Outcome of Board Meeting

Krebs Biochemicals & Industries Limited CIN: L24110AP1991PLC103912 October 29, 2026 To, To, BSE Limited National Stock Exchange of India Ltd P J Towers, Dalal Street, Exchange Plaza, Bandra Kurla Complex, Fort, Mumbai- 400 001. Bandra(E), Mumbai- 400 051. Scrip Code : 524518 Scrip Code : KREBSBIO Dear Sir / Madam, Sub: Outcome of Board Meeting – Unaudited Financial Results for the 2nd quarter and half year ended 30th September 2026. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that the Board of Directors of the Company at its meeting held today approved and taken on record the following: 1. Unaudited Financial Results of the Company for the 2nd quarter and half year ended September 30, 2026. 2. Limited Review Report by the Auditors on the Unaudited Financial Results for the 2nd quarter and half year ended September 30, 2026. The Meeting of the Board of Directors commenced at 11:30 am and concluded at 12:55 p.m. The above is for your information and record. Thanking you, Yours Faithfully, For Krebs Biochemicals and Industries Limited Rakesh R Kalbate Company Secretary & Compliance Officer Encl.: a/a. Regd. Office : Kothapalli (V), Kasimkota (M), Anakapalli, Visakhapatnam, Andhra Pradesh-531 031 Tel : 040-66808040, Website: www.krebsbiochem.com, Email: com_sec@krebsbiochem.com KREBS BIOCHEMICALS & INDUSTRIES LIMITED CIN:L24110AP1991PLC103912 Registered Office: Kothapalli Village, Kasimkota Manda!, Anakapalli, Visakhapatnam, Andhra Pradesh -531 031 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 (Rs. In lacs) Quarter Ended Half Year Ended Sr.No Particulars 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 IUnauditedl IUnauditedl IUnauditedl IUnauditedl IUnauditedl IAuditedl 1 Revenue from Operations 579.03 698.35 416.74 1,277.38 964.83 2,373.16 2 Other Income 3.74 15.65 0.67 19.39 1.84 202.63 3 Total Income (1+21 582.77 714.00 417.41 1296.77 966.67 2 575.79 4 Expenses al Cost of Material Consumed 28.76 (0.03 0.16 28.73 4.09 5.05 bl Purchase of Stock-in -Trade 3.78 50.69 - 54.47 - c) Changes in Inventories of Finished goods, Work-In-Progress 96.93 (9.54) 87.39 24.99 34.01 d) Emplovee Benefits Expenses 283.35 277.92 268.98 561.27 544.09 1038.80 el Finance Costs 190.18 188.05 173.29 378.23 338.30 708.59 f) Depreciation and Amortisation Expense 160.54 158.78 162.43 319.32 322.30 642.33 Ig ) Other Expenses 359.08 296.61 426.83 655.69 879.61 1840.32 Total Exoenses (4) 1122.62 962.48 1 031.69 2 085.10 2113.38 4 269.10 5 Profit I (Lossl before exceptional items and tax (3-41 (539.85) (248.48 (614.281 (788.33) (1,146.71) (1,693.311 6 Exceptional Items - - - 7 Profit I {Loss) before Tax {5 + 61 {539.85) {248.48 {614.28) {788.33) {1,146.71) {1,693.31) 8 Tax Expense a) Current Tax - - - - - - b) Tax pavment of earlier vears - - - - - cl Deferred Tax - - - - - - 9 Profit I {Loss) for the period from Continuing Operations (7+8) {539.85) (248.48) (614.28) (788.33) {1146.71) (1693.31) 10 Other Comprehensive Income i Items that will not be reclassified to profit or Loss 41.72 ii Income tax relating to items that will not be reclassified to profit or Loss - - - - - - - - iii Items that will be reclassified to profit or Loss iv Income tax relating to items that will be reclassified to profit or Loss - - - - Other Comprehensive Income (Net ofTaxl 41.72 11 Total Comorehensive Income for the period{9+10l {539.85) (248.48) (614.28) (788.33) {1146.71) {1651.59) 12 Paid-up Eouitv Share Capital {Face Value Rs. 10/-each) 2,156.06 2,156.06 2,156.06 2,156.06 2,156.06 2,156.06 - - - - 13 Other Eouitv (19,536.61) 14 Earning Per Share {of Rs.10/-each) (not Annualised) a) Basic (2.50) {1.15) (2.85) (3.66) (5.32) (7.851 b) Diluted (2.50) (1.15) (2.85) (3.66) (5.32) (7.85) 15 Net Worth (including Retained Earnings) - - - - (16,275.47) Notes: 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on Oct 29, 2026. 2 The Statutory Auditors have carried out audit of the aforesaid results and have issued their "Unmodified Report" thereon. The above financial results are prepared in accordance with the Indian Accounting Standards( IND AS) as prescribed under Section 133 of the companies Act,2013 and are in compliance with presentation and disclousure requirements of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations,2015 (as Amended). 4 The Company is operating in one segment only hence no segment results have been disclosed. 5 As at Sep 30,2026 the Company does not have any Subsidiary/Associate/Joint venture company(ies). The Operations of the Company's Vizag manufacturing unit continued to remain closed pursuant to order dated 7th February 2025 passed by the Andhra Pradesh Polluation Control Board. The company has taken various steps in this matter and is in constant dialogue with the Polluation Control Board for revocation of the closure order. 7 Figures of the previous period have been regrouped to confirm to the figures of the current period's classification wherever necessary. The Board of Directors have approved the amalgamation of Krebs Biochemicals & Industries Limited with lpca Laboratories Limited at their meeting held on June 26, 2026, subject to necessary consents/ approvals. The appointed date for this scheme of amalgamation is April 1, 2026. , «'·'Cals, . -:.. ...0. . ~ CY 1/ 0::. >' c Man umar Jain ·-· 1 "' Place: Mumbai Jill - Managing Director/ CEO Date: Oct 29,2026 \ ·II\ /.;":. i DIN : 06477976 ;\..,.G'- /.. "· '/ KREBS BIOCHEMICALS & INDUSTRIES LIMITED CIN:L24110AP1991PLC103912 Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh -531 031 Unaudited Statement of Assets and Liabilities as at Sep 30, 2026 (Rs. In Lacs) As at As at Particulars 30.09.2026 31.03.2026 Unaudited Audited ASSETS: Non-current assets : (a) Property, Plant and Equipment 13,917.55 14,142.05 (b) Capital Work-In-Progress 162.39 158.68 (c) Other Intangible Assets 19.61 28.83 (d) Intangible Assets under Development - - (e) Financial Assets (i) Other financials assets 163.88 271.36 (f) Other Non-Current Assets 831.63 761.53 Total Non-current assets 15,095.06 15,362.45 Current assets : (a) Inventories 422.61 570.36 (b) Financial Assets (i) Trade receivables 0.43 0.43 (ii) Cash & cash equivalents 12.59 12.91 (iii) Other financial assets 6.25 18.37 (c) Other Current Assets 340.90 360.15 Total Current assets 782.78 962.22 Total Assets 15 877.84 16 324.67 EQUITY AND LIABILITIES: Equity: (a) Equity Share Capital 2,156.06 2,156.06 (b) Other Equity 19,219.86 (18,431.53 Total Equity 17,063.80' (16,275.47 Liabilities : Non-current liabilities : (a) Financial Liabilities (i) Borrowings 15,450.00 16,355.00 (ii) Other Financial Liabilities 113.51 160.82 (b) Provisions 277.74 277.74 (c) Other Non Current Liabilities 4,500.00 4,500.00 Total Non-current liabilities 20,341.25 21,293.56 Curent Liabilities (a) Financial Liabilities (i) Borrowings 7,248.56 6,128.82 (ii) Trade Payables (a) Total outstanding dues of micro and small enterprises 93.39 116.92 (b) Total outstanding dues of creditors other than micro and small enterprises 1,151.28 1,258.92 (iii) Other Financial Liabilities 2,608.13 2,239.02 (b) Other Current Liabilities 1,416.63 1,493.37 (c) Provisions 82.39 69.53 Total Current Liabilities 12,600.39 11,306.58 Total Equity and Liabilities 15,877.84 16 324.67 \C.als ~ / ... CJ !fl I ~ S. Manish Kumar Jain Place: Mumbai ~ -·~ 1anaging Director/ CEO Date: Oct 29, 2026 ~&- · DIN: 06477976 KREBS BIOCHEMICALS & INDUSTRIES LIMITED CIN:L24110AP1991PLC103912 Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh -531 031 Audited Standalone Cash Flow Statement for the Half year ended September 30, 2026 (Rs. In Lacs) Half Year ended Ha [Showing first 8,000 characters — download PDF for full document]